Repression of oxidative phosphorylation sensitizes leukemia cell lines to cytarabine

dc.contributor.authorYucel, Burcu
dc.contributor.authorSonmez, Mehmet
dc.date.accessioned2025-05-10T15:24:03Z
dc.date.issued2018
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjectives: Leukemia is a group of bone marrow cancers and drug resistance is one of the challenges in treatment. Caffeic acid phenethyl ester’s (CAPE’s) anti-proliferative and apoptotic properties have been reported in leukemia cell lines. However, CAPE’s effect on drug resistance and cellular metabolism is still unknown. Thus, in this study, we aimed to explore CAPE’s effect on drug resistance and oxidative phosphorylation (oxphos). Methods: Leukemia cell lines NB-4, HL-60, and K562 were treated with CAPE. ATP-based cell viability assay was used. For gene expression studies, RNAs were isolated and reverse transcribed. To investigate CAPE’s effect on mitochondrial dysfunction in AML cell lines, we examined oxygen consumption rates (OCRs) in our cell lines. Results: We found 5 ?M CAPE sensitized all cell lines to cytarabine. This similar effect was also observed in the Decitabine-resistant K562 cell line. However, no difference was seen in MDR1 expression upon CAPE treatment in all cell lines. OCR significantly decreased upon CAPE treatment in all cell lines, while the expression of key regulatory glycolytic enzymes increased in K562 and NB-4 cell lines. Expression of STAT3 also changed upon CAPE treatment. Discussion: Our results suggested that CAPE alters cellular metabolism by decreasing oxphos and increasing glycolysis in K562 and NB-4 cells. Furthermore, CAPE treatment altered STAT3 expression regarding alterations in oxphos and aerobic glycolysis. Conclusion: Our results suggest a new property of CAPE, which is oxphos repression, and a presumptive link between altered metabolism and drug resistance. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
dc.description.sponsorshipFigen Celep Eyupoglu of the Medical Biology Department; Karadeniz Technical Faculty School of Medicine
dc.identifier.doi10.1080/10245332.2017.1402454
dc.identifier.endpage336
dc.identifier.issn1024-5332
dc.identifier.issue6
dc.identifier.pmid29139328
dc.identifier.scopus2-s2.0-85034077017
dc.identifier.scopusqualityQ3
dc.identifier.startpage330
dc.identifier.urihttps://doi.org/10.1080/10245332.2017.1402454
dc.identifier.urihttps://hdl.handle.net/20.500.14730/6614
dc.identifier.volume23
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofHematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250302
dc.subjectCAPE; cytarabine; glycolysis; leukemia; oxidative phosphorylation
dc.titleRepression of oxidative phosphorylation sensitizes leukemia cell lines to cytarabine
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
6614.pdf
Boyut:
1.47 MB
Biçim:
Adobe Portable Document Format